Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 10, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 345,000 ordinary shares of 25 pence each.
- Purchase Price: 1,434.7901 pence per share.
- Treasury Shares Held: 188,601,678 shares following the transaction.
- Shares in Issue: 5,795,922,242 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program authorized by shareholders at the Annual General Meeting on May 17, 2006. The company executed this purchase on August 10, 2006, and intends to hold the acquired shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Points
- Verify the total cost of the 345,000 shares purchased at 1,434.7901 pence per share.
- Confirm the updated total number of shares in issue (5,795,922,242) against the company's latest capital structure reports.
- Check the remaining authorization limit for share buybacks following this transaction.